Excited to have Robert Ang, CEO of Vor Bio, join us on the latest episode! With a focus on developing next-gen cancer therapies, Vor Bio is making waves in the biotech industry. In this episode hosted by Rahul Chaturvedi, CEO of Clora, Robert shares insights into the current state of cancer therapies and Vor Bio's innovative approaches, including shielded stem cell transplants and CAR T-cell therapies targeting hematologic malignancies like AML and MDS. He also discusses his experience serving on boards and his unique approach to talent and building teams, prioritizing passion and impact over titles. Tune in for an insightful discussion on the future of cancer treatment and the role of VorBio in shaping it! #Biotech #CancerTherapies #Innovation #Leadership #Healthcare #Podcast #Biotech2050 Listen now: https://lnkd.in/dRhnCm5a
Biotech2050’s Post
More Relevant Posts
-
Clora CEO Rahul Chaturvedi hosts an inspiring new episode of the Biotech2050 podcast featuring Robert Ang, CEO of Vor Bio. Dive into an engaging discussion on next-gen cancer therapies, including Vor’s shielded CD33-deleted stem cell transplants and CAR-T cell therapies for AML and MDS. Robert also shares his unique approach to building passionate and impactful teams. Listen using the link below. #Clora #biotech #podcast #cancer #stemcelltransplant
Excited to have Robert Ang, CEO of Vor Bio, join us on the latest episode! With a focus on developing next-gen cancer therapies, Vor Bio is making waves in the biotech industry. In this episode hosted by Rahul Chaturvedi, CEO of Clora, Robert shares insights into the current state of cancer therapies and Vor Bio's innovative approaches, including shielded stem cell transplants and CAR T-cell therapies targeting hematologic malignancies like AML and MDS. He also discusses his experience serving on boards and his unique approach to talent and building teams, prioritizing passion and impact over titles. Tune in for an insightful discussion on the future of cancer treatment and the role of VorBio in shaping it! #Biotech #CancerTherapies #Innovation #Leadership #Healthcare #Podcast #Biotech2050 Listen now: https://lnkd.in/dRhnCm5a
To view or add a comment, sign in
-
-
🔬 Exciting News in Cancer Research! 🔬 🌟 Firefly Bio: Revolutionizing Cancer Treatment 🌟 Firefly Bio, a cutting-edge biotech company, is making waves in the fight against cancer. They’ve developed a groundbreaking therapy called degrader-antibody conjugates (DACs), combining the best of antibody-drug conjugates (ADCs) with the power of protein degraders. Why DACs Matter? DACs promise to be more selective and potent in delivering their payload to cancer cells, while sparing healthy tissue. Plus, they can target new biology beyond the three mechanisms of action approved in ADCs. Funding and Dream Team Firefly Bio has secured a whopping $94 million in funding, with support from Eli Lilly and other investors. Their dream team includes experts from Versant Ventures, Genentech, Merck, Novartis, and even Nobel laureate Carolyn Bertozzi! Mission: Solid Tumors Firefly Bio’s mission? Tackling solid tumor targets that have faced dose-limiting toxicities. They’ve already selected a lead asset and proven their concept. #CancerResearch #FireflyBio #DACs #Innovation
To view or add a comment, sign in
-
🎙️ Excited to share a podcast which delves deep into the intricacies of ovarian cancer biomarker testing and pre-analytical phase challenges: https://lnkd.in/gQzqqGb2. You’ll learn how to meet these challenges, including the best- practices for tissue collection and preservation. Joined by eminent experts Assoc. Prof. Martina Murphy and Assoc. Prof. Caterina Marchiò, this podcast also unravels the significance of genetic alterations identification in ovarian cancer. 🔍 Clinical Takeaways: ✅ Adherence to guidelines is crucial for proper sample fixation and DNA integrity preservation. ✅ Effective patient-oncologist communication is pivotal for understanding biomarker significance and the role of comprehensive testing for personalized medicine. ✅ Multidisciplinary collaboration is key for informed decision-making and patient engagement. ✅ Identifying clinical-relevant biomarkers like BRCA1/BRCA2 and HRD status informs personalized treatment in ovarian cancer. Don't miss out on this enriching conversation! Tune in now and stay ahead in the realm of oncology and personalized medicine. #OvarianCancer #BiomarkerTesting #PersonalizedMedicine #Oncology #PodcastSeries
To view or add a comment, sign in
-
🚀 Years Of Research At Navaux Begins To Redefine Hepsin's Role In Cancer Genesis 🚀 At Navaux, we’re on a mission to revolutionize cancer detection with our cutting-edge research in non-invasive early detection. We’re thrilled to share a major breakthrough in our work with serine proteases, particularly hepsin. While many have explored hepsin before, our team has uncovered critical differences between full-length hepsin and circulating, activated hepsin—insights that had eluded others. This discovery is a significant step forward in understanding cancer biomarkers and improving early detection methods. We’re proud to announce that we’ve completed epitope mapping and filed patents for our innovative findings related to hepsin. This advancement brings us closer to transforming how cancer is detected and treated, ultimately paving the way for better patient outcomes. A huge thank you to our dedicated team for their hard work and perseverance. We’re excited about the future and the potential impact of our discoveries! 🔬💡 Stay tuned for more updates as we continue to advance the field of cancer research. #CancerResearch #Innovation #EarlyDetection #Hepsin #Navaux #MedicalBreakthrough #Biotech
To view or add a comment, sign in
-
Inspiring Leader in Tech | Caring for People | Bioinformatics & Clinical Expert | PhD & Early Career Consultant
🌟 Exciting Review on Cancer Biomarkers Published in Cell A groundbreaking review marking the 50th anniversary of Cell magazine has been shared, & it's a must-read for anyone interested in the evolving landscape of oncology biomarkers. "Cancer biomarkers: Emerging trends and clinical implications for personalized treatment" meticulously synthesizes main research & collaborative expertise of leaders in the field. 🎯 Highlights: 🧬Integration of Biomarkers: how cancer biomarkers are crucial for the shift towards personalized treatment in oncology. 💊Tailored Therapies: It stresses the empowerment of oncologists to customize treatments based on the molecular makeup of tumors, heralding a new era in precision oncology. 🔭Future Horizons: The authors discuss the future of managing solid tumors, driven by innovations in profiling circulating tumor fractions & understanding the immune microenvironment. 🔗 Full article free here 👇👇👇: https://lnkd.in/dCAx4Rkp ⚕️A tip of the hat to the authors for this enlightening synthesis Antonio Passaro fabrice andre Peters Solange et al. #ESMO #PrecisionOncology #CancerResearch #Cell #biomarkers #genomics #WGS #ctDNA #liquidbiopsy
To view or add a comment, sign in
-
-
🎙️ Excited to share a podcast which delves deep into the intricacies of ovarian cancer biomarker testing and pre-analytical phase challenges: https://lnkd.in/ggURuKXx Joined by eminent experts Assoc. Prof. Martina Murphy and Assoc. Prof. Caterina Marchiò, this podcast unravels the significance of genetic alterations identification in ovarian cancer. 🔍 Clinical Takeaways: ✅ Adherence to guidelines is crucial for proper sample fixation and DNA integrity preservation. ✅ Effective patient-oncologist communication is pivotal for understanding biomarker significance and the role of comprehensive testing for personalized medicine. ✅ Multidisciplinary collaboration is key for informed decision-making and patient engagement. ✅ Identifying clinical-relevant biomarkers like BRCA1/BRCA2 and HRD status informs personalized treatment in ovarian cancer. Don't miss out on this enriching conversation! Tune in now and stay ahead in the realm of oncology and personalized medicine. #OvarianCancer #BiomarkerTesting #PersonalizedMedicine #Oncology #PodcastSeries
Ovarian Cancer: Pre-analytical phase challenges and biomarker testing | COR2ED
amoy-diagnostics-co-ltd.shp.so
To view or add a comment, sign in
-
🤔 Still hungry for some biotech news before the end of the week? 💡Researchers at the UZ Leuven and KU Leuven led by Prof. Jeroen Dekervel worked together with the lab of Diether Lambrechts (VIB-KU Leuven Center for Cancer Biology) to find a new biomarker that can help predict immunotherapy response in liver cancer patients. 🔬Immunotherapy shows great promise in cancer treatment, but unfortunately, patients don’t always respond to it. While deemed impossible up to now, a new study published in Nature Portfolio Communications details how the research team used single-cell technologies to discover a biomarker that can predict if a patient will respond to immunotherapy. Read the full press release👇 https://lnkd.in/eaAwBTyM #oncology #cancer #livercancer #immunotherapy #biomarker #innovation
Home
To view or add a comment, sign in
-
✨🧬 How is Next-Generation Sequencing (NGS) transforming precision cancer testing 🧬✨ Read here: https://lnkd.in/dDRbSc7R NGS stands out as a beacon of hope, offering unprecedented accuracy and speed in diagnosing and treating cancer. This breakthrough technology is not just about identifying cancer earlier; it’s about tailoring treatments to the genetic makeup of each patient's cancer, ensuring more effective and less invasive therapeutic strategies. Dara McCreary Discover how NGS is revolutionizing oncology, making targeted therapy a reality, and bringing us closer than ever to turning the tide against cancer. Illumina MGI Thermo Fisher Scientific PacBio #PrecisionMedicine #CancerResearch #NGSSequencing #Oncology #InnovationInHealthcare #dnasequencing #sanger #oxfordnanopore #LIMS #ELN #LabInformatics #Labsoftware #LabInstruments #PrecisionResearch #precisiononcology
To view or add a comment, sign in
-
-
🌟 Exciting Review on Cancer Biomarkers Published in Cell A groundbreaking review marking the 50th anniversary of Cell magazine has been shared, & it's a must-read for anyone interested in the evolving landscape of oncology biomarkers. "Cancer biomarkers: Emerging trends and clinical implications for personalized treatment" meticulously synthesizes main research & collaborative expertise of leaders in the field. 🎯 Highlights: 🧬Integration of Biomarkers: how cancer biomarkers are crucial for the shift towards personalized treatment in oncology. 💊Tailored Therapies: It stresses the empowerment of oncologists to customize treatments based on the molecular makeup of tumors, heralding a new era in precision oncology. 🔭Future Horizons: The authors discuss the future of managing solid tumors, driven by innovations in profiling circulating tumor fractions & understanding the immune microenvironment. 🔗 Full article free here 👇👇👇: https://lnkd.in/dFMXkWbv ⚕️A tip of the hat to the authors for this enlightening synthesis Antonio Passaro fabrice andre Peters Solange et al. #ESMO #PrecisionOncology #CancerResearch #Cell #biomarkers #genomics #WGS #ctDNA #liquidbiopsy
To view or add a comment, sign in
-
-
🌟 Taking Extra Steps: Understanding AKT1 in Cancer Treatment! 🧬 We're excited to share our latest project investigating the AKT1 oncogene and its role in the PI3K/AKT signaling pathway. By exploring AKT1 mutations, we aim to uncover new insights into cancer resistance mechanisms and potential therapeutic targets. This study is part of our commitment to advancing cancer research and developing innovative treatments. Check out the enclosed diagram illustrating the key pathways and mechanisms involved! 🌐🧫 #AKT1 #CancerResearch #Oncogenes #Genomics #PI3KAKTPathway #HealthcareInnovation #Biotech #ScientificDiscovery
To view or add a comment, sign in
-